JEMPERLI (dostarlimab-gxly) RUBY Trial Results
Learn more about the RUBY Trial results for JEMPERLI.
Related Articles
Global Reach
Bringing Radioligand Therapy (RLT) Clinical Trials to Your Fingertips We are uniquely positioned at the heart of Theranostics. We’re dedicated to increasing awareness about Theranostics…
Concluding Thoughts on the Context of Physical Activity and Sedentary Behavior: Episode 6
In this conclusive sixth episode of our mini-series on the context of sedentary behavior and physical activity, we recap the importance of understanding thes…
Advances in Staging and Personalized Radiation Therapy for High-Risk Localized Prostate Cancer – Leslie Ballas
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Leslie…
Managing Nonmetastatic Castration-Resistant Prostate Cancer – Zachary Reardon
Zach Klaassen and Zach Reardon delve into the nuances of managing nonmetastatic castration-resistant prostate cancer (nmCRPC) in clinical practice. Dr. Reardon discusses the evolving landscape…
Tumor Suppressor Gene Signature Predicts Early Progression in mHSPC – Marta Garcia de Herreros
Neeraj Agarwal interviews Marta Garcia de Herreros about presentation on tumor suppressor gene (TSG) signatures in metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Garcia de Herreros…
PATCH Trial Evaluates Transdermal Estradiol in Non-Metastatic Prostate Cancer – Duncan Gilbert
Duncan Gilbert discusses the PATCH trial, comparing transdermal estradiol with LHRH agonists for androgen suppression in non-metastatic prostate cancer. Dr. Gilbert discusses the trial design,…
Radium-223 Plus Enzalutamide Improves Survival in mCRPC: PEACE-3 Trial Results, Journal Club – Rashid Sayyid & Zachary Klaassen
Rashid Sayyid and Zachary Klaassen discuss the resurgence of radium-223 in treating metastatic castration-resistant prostate cancer (mCRPC), focusing on the PEACE-3 trial results. The conversation…
Utilizing the Decipher mRNA Score for Risk Stratification in mHSPC – David Morris and Ashley Ross
Ashley Ross and David Morris discuss the use of the Decipher Genomic Classifier in metastatic hormone-sensitive prostate cancer (mHSPC). They explore how Decipher can help…
The biggest medical advances of 2024
The biggest medical advances of 2024 will be remembered as significant long into the future.
EMBARK Trial: Age-Stratified Analysis of Enzalutamide in High-Risk Biochemically Recurrent Prostate Cancer – Neal Shore
Zach Klaassen interviews Neal Shore about the EMBARK trial’s post hoc analysis by age. The study examines the efficacy of enzalutamide alone or combined with…